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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2015, ElsevierDespite the recent enormous advances in medicine, high mortality and morbidity rates among
the chronic kidney disease (CKD) patients remain an important but unresolved issue. Cardio-
vascular disease is a major cause of mortality and morbidity in patients with CKD. Abnormal
left ventricular geometry and functions are common in this patient group and have been
proven to be correlated with a high cardiovascular mortality/morbidity and all-cause mortal-
ity. For this reason, echocardiographic study plays an important role in evaluating cardiac
structure and functions as well as in stratifying prognostic risk. We here summarize the re-
ported findings on the usefulness of echocardiographic methodologies and identify their roles
in diagnostic and prognostic clinical approaches.
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798 Y.-W. Liu et al.(ESRD) is still notorious for high mortality.4,7 There are
several possible explanations for poor prognosis of CKD
patients, including traditional cardiovascular risk factors
(i.e., hypertension, diabetes mellitus, and dyslipidemia),
nontraditional factors (e.g., malnutrition, inflammation,
and oxidative stress), and CKD-related risk factors (e.g.,
atherosclerosis, anemia, altered calciumephosphate
metabolism).8e15 These factors may contribute to the
development and deterioration of the coronary artery dis-
ease (CAD), microvasculopathy, valvulopathy, cardiomyop-
athy, and arrhythmias.9,16e22
Cardiac abnormalities, especially abnormal left ven-
tricular (LV) geometry and functions, are frequently
detected in CKD patients and have been proven to be
correlated with high cardiovascular mortality/morbidity
and all-cause mortality.2,3,23e25 Early identification of such
high-risk patients should thus allow physicians to optimize
the therapeutic interventions, which may lower morbidity
and mortality.7
Role of echocardiography
Nowadays, cardiac magnetic resonance imaging (cMRI) is
the widely accepted reference standard of noninvasive
imaging modalities to evaluate cardiac morphology (e.g.,
LV volume and mass) and function [e.g., ejection fraction
(EF) and cardiac output].26 However, there are several
major limitations of cMRI in daily practice, such as its high
costs, nonportability, and having little or no prognostic
evidence of several CVDs.27 These factors limit its clinical
application. In addition, although the risk of gadolinium
toxicity in advanced CKD patients is rare, the serious
complication of nephrogenic systemic fibrosis is still the
major concern.28,29
Echocardiography is another option to evaluate cardiac
geometry and functions. Although echocardiography is
operator dependent, over the past several years the accu-
racy of echocardiographic measurements had been proven
to be closely correlated with histologic findings and had
also been well validated in epidemiologic studies. There-
fore, echocardiographic study may play a critical role in
evaluating cardiac functions, stratifying prognostic risk
factors, and assessing the effect of therapeutic
interventions.
Traditionally, two-dimensional echocardiography (2DE)
and M-mode imaging have been viewed as capable of
assessing LV geometry and quantifying LV mass, end-
diastolic and end-systolic volumes, and systolic func-
tion.30 Furthermore, the Doppler modality can provide in-
direct information about LV relaxation, which indicates the
LV diastolic function.31
LV hypertrophy
LV hypertrophy is one of the most common cardiac geo-
metric abnormalities in CKD patients.32e34 It is also
acknowledged as an independent prognostic predictor,
especially among dialysis patients.34e36 Therefore, LV hy-
pertrophy is regarded as a treated target.
The finding of an increase in LV hypertrophy with
simultaneous decrease in renal function indicates theinverse association between the LV mass and the stage of
renal failure.23,32,37 LV hypertrophy is reported in 16e50%
of early and intermediate CKD (Stages 1e3) patients,
50e70% of advanced CKD (Stages 4 and 5) patients, and in
up to 70e90% of regular dialysis patients.22,25,32,33,37 Such
variation between different reports may result from the
different cutoff values of LV hypertrophy.32,33,38 Notwith-
standing this variation, the prognostic power of LV hyper-
trophy in CKD patients is well recognized.
Given that LV mass is recognized to be proportional to
body size, it should be indexed by body surface for clinical
studies and daily practice. According to the recommenda-
tions of the American Society of Echocardiography (ASE)
and the European Association of Echocardiography (EAE),
the cutoff value of LV hypertrophy is > 115 gm/m2 for men
and >95 gm/m2 for women.30 However, hemodialysis pa-
tients may be subject to large body-weight variations,
which may lead to evaluation errors by body surface
indexation.32,39 Thus, some experts recommended indexing
LV mass by height to the 2.7 power to assess LV mass
accurately in hemodialysis patients.40 Nevertheless, there
has not been to date any head-to-head comparison study to
address the fundamental question of whether indexation by
height can more accurately evaluate LV mass than index-
ation by body surface in hemodialysis patients. Therefore,
standardization of LV mass formulas by echocardiography
guidelines should be helpful to prevent variations between
clinical studies and patient cares.LV diastolic function
Renal impairment and cardiac dysfunction frequently
coexist. Several mechanisms account for CKD-related car-
diomyopathy, including CAD, microvasculopathy, reduction
of coronary reserve, and alternations of LV geometry in
response to the overload of pressure and volume. To
maintain an adequate cardiac output, ventricular remod-
eling occurs in response to such alternations. However,
such ventricular remodeling is pathologic and will lead to
chamber dilatation, LV hypertrophy, and LV systolic as well
as diastolic dysfunction. LV diastolic dysfunction is common
in CKD patients,22,32,33,41 with causes being multifactorial.
There is evidence that impairment of LV diastolic relaxation
develops along with the activation of circulating plasmin-
ogen activator inhibitor-1.42 Myocardial fibrosis is also a
major determinant of diastolic function.43e46 The plasma
level of carboxy-terminal peptide of procollagen type I has
thus been suggested as a useful marker for determining the
level of fibrotic activity44e46 and diastolic dysfunction.47,48
Diastolic function is related to myocardial relaxation and
LV compliance/stiffness. The former is determined by load,
myocardial inactivation, and asynchrony,49 whereas the
latter describes the relationship between LV diastolic
pressure and volume, and is determined by the car-
diomyocytes and the interstitial matrix. Based on the ASE/
EAE guidelines,31 comprehensive LV diastolic function
should be evaluated with several modalities, such as 2DE,
which can quantify LV mass, left atrial (LA) volume
(Figure 1A), and LA function. It is also noteworthy that the
measurement of LA volume is highly reliable and clinically
important to assess LV diastolic function. Moreover, LA
Figure 1 An example of images captured from an end-stage renal disease patient (49-year-old male) with low E/e0 ratio. (A) End-
systolic left atrial (LA) volume with a volume index of 28.6 mL/m2 was acquired in the apical four-chamber view. LA
volume Z 54 mL; body surface area Z 1.89 m2. (B) Pulsed-wave Doppler, and (C, D) tissue Doppler were performed in the apical
four-chamber view to acquire mitral inflow early diastolic velocity (parameter E), septal, and lateral tissue Doppler signals (e0) of
the mitral annulus. Average septal e0 Z 8 cm/s; average lateral e0 Z 10 cm/s. (E) Echocardiography parameters: the average
(septal and lateral) e0 velocity was used to calculate the E/e0 ratio.
Echocardiograph in CKD 799volume index is an independent prognostic predictor in CKD
patients.50,51 However, as dilated LA is not uncommon in
patients without diastolic dysfunction, such as anemia and
bradycardia, it is important to interpret LA volume with
patients’ clinical condition, other chambers’ volumes, and
Doppler parameters of LV relaxation.
To assess LV diastolic function, pulsed-wave (PW)
Doppler, which is performed in the apical four-chamber
view to acquire mitral inflow velocities, is used to evaluate
LV filling parameters (Figure 1B). The primary transmitral
PW Doppler measurements include peak E (early diastole)
and peak A (late diastole) velocities, the E/A ratio, the
deceleration time of the early filling velocity, and the iso-
volumic relaxation time. The mitral inflow patterns include
normal, impaired LV relaxation (E/A < 1, grade 1 diastolic
dysfunction), pseudonormal LV filling (E/A > 1, grade 2
diastolic dysfunction), and restrictive LV filling (E/A > 2,
grade 3 diastolic dysfunction). Farshid et al52 reported that
diastolic dysfunction is a powerful predictor of all-cause
mortality in advanced CKD patients. However, several
conditions, such as tachycardia, arrhythmias, andconduction system disease, will make transmitral PW
Doppler parameters difficult to interpret.
The evidence of LV diastolic dysfunction provided by
echocardiography is an increased LV filling pressure without
other causes such as systolic dysfunction and valvular heart
diseases. Currently, the most useful modality to assess LV
diastolic function is a combination of mitral inflow Doppler
velocity and mitral annulus tissue Doppler velocity. Average
early mitral velocity (E) to early mitral annulus tissue ve-
locity (e0) ratio has been proved to be well correlated with
LV filling pressure or LA pressure. PW Doppler is performed
in the apical four-chamber view to acquire mitral inflow
velocities to evaluate early mitral velocity (expressed as E;
Figure 1B). Tissue Doppler imaging (TDI) is performed in the
apical four-chamber view to acquire mitral annular veloc-
ities, that is, the early diastolic mitral annular velocity
(expressed as e0) and the late diastolic mitral annular ve-
locity (expressed as a0; Figure 1C and D). The E/e0 ratio can
be used to predict LV filling pressures,31,41 where it is rec-
ommended to use the average e0 velocity obtained from the
septal and the lateral mitral annuli. A previous study
800 Y.-W. Liu et al.showed that increased E/e0 indicated a more severe cardiac
fibrosis and high LV filling pressure in dialysis patients.41
However, to interpret E/e0 in these patients, it is impor-
tant to consider their age, underlying CVD, and any ab-
normalities noted in the echocardiogram.31 In other words,
E/e0 alone should not be used as the data or the gold
standard to draw the conclusion on LV diastolic function.LV systolic function
Although most CKD patients have preserved LVEF (50%),
reduced LVEF is well recognized as an independent prog-
nostic predictor in CKD patients.7,25,53 Therefore, cardiac
functions in CKD patients have been studied extensively
with conventional 2DE. The LV systolic function is usually
evaluated using 2DE with M-mode analysis to evaluate
fractional shortening, EF, and/or midwall fraction and
shortening,30 but these measurements merely provide
semiquantitative evaluation and are insensitive in detect-
ing early deterioration of cardiac function and early
changes of left ventricle in CKD patients.54
Using pulsed TDI [i.e., systolic myocardial velocity (s0) at
the septal and lateral mitral annuli; Figure 2A and B],
deterioration of LV function can be detected in CKD pa-
tients.54 Although TDI has been proven to be more accurate
and sensitive than conventional echocardiography for
detecting subtle systolic dysfunction, TDI-derived strain
measurement has several potential pitfalls and limitations,
including signal noise, artifacts, temporal resolution, and
suboptimal interrogation angling.55Two-dimensional speckle-tracking
echocardiography imaging of myocardial
deformation
Global LVEF reflects the sum of all regional shortening in
the left ventricle. Methods that are able to measure LV
regional function should be more sensitive than global EF
for identifying systolic dysfunction. In recent years, a
relatively novel modality, speckle-tracking echocardiogra-
phy (STE), has been comprehensively studied to illustrate
the subtle deterioration of global and regional cardiac
systolic function. Speckles are natural acoustic markers,
seen as small and bright elements in conventional gray-
scale ultrasound images,56 and on ultrasound images, they
are distributed equally in the myocardium. The distanceFigure 2 Pulsed tissue Doppler imaging from the (A) septal andbetween selected speckles is measured simultaneously
from multiple regions of interest and is a direct measure of
myocardial deformation (strain). In other words, strain is
the fractional change in an object’s dimension in compar-
ison to the object’s original dimension. The myocardial
deformation of a cardiac cycle consists of three major
components, namely, longitudinal, circumferential, and
radial aspects. Among these three deformation aspects,
longitudinal strain is well studied and has been proven to be
able to detect subtly deteriorated LV global and regional
systolic functions.
LV global peak systolic longitudinal strain (GLS), ob-
tained from 2D-STE with strain analysis (Figure 3), is the
ratio of the maximal change in myocardial longitudinal
length in systole to the original length. During systole, LV
myocardium in the longitudinal direction shortens and GLS
is represented by a negative value. The more negative the
GLS value, the better the LV function. Compared with LVEF,
GLS is a more sensitive, objective, and reproducible mo-
dality for assessing cardiac function. In addition, TDI-
derived strain measurement has several potential pitfalls
and limitations, such as signal noise, artifacts, temporal
resolution, and suboptimal interrogation angling.55,57,58 STE
has also been introduced as a method for angle-
independent quantification of myocardial strain.59
Nowadays, it is well accepted that STE can reflect
regional myocardial deformation and detect small alter-
nations in systolic function.60 In our previous studies, we
demonstrated the deterioration of LV systolic function in
heart failure patients with preserved LVEF and CKD patients
using STE with GLS analysis.9,21,22,61
Notwithstanding CAD is common in CKD patients and
approximately 30e40% of ESRD patients experience
ischemic events.62,63 Accumulating evidence has revealed
that STE is a powerful tool for indentifying the early
changes and subtle abnormalities that develop with
ischemic myocardium, and is recommended as a tool to
evaluate patients with CAD.64,65 We thus applied STE with a
longitudinal strain analysis in hemodialysis patients and
showed that longitudinal strain is useful for a noninvasive
diagnosis of CAD in hemodialysis patients; however,
measuring the level of circulating biomarkers, including
cTnT, is unable to help in the screening for CAD.16
Despite significant advances in modern medical therapy,
neither aggressive medical treatment nor multiple inter-
vention strategies have been found to improve prognosis in
ESRD patients.66,67 This lack of documented efficacy may be
attributable to the fact that interventions are studied at(B) lateral mitral annuli in a chronic kidney disease patient.
Figure 3 Processing and presentation of global left ventricular peak systolic longitudinal strain (GLS). Values of the peak systolic
longitudinal strain from the apical long-axis, apical four-chamber, and apical two-chamber views were obtained from automated
function imaging software. (A) Tracking quality approval screen: segments with adequate tracking are shown with a “V” mark. (B)
The average value of peak systolic longitudinal strain in each segment calculated from three apical views was used to generate a
parametric display, named GLS. A2C Z apical two chamber; A4C Z apical four chamber; apLat Z apical lateral wall;
apSept Z apical septum; basLat Z basal lateral wall; basSept Z basal septum; GLPSS Z global longitudinal peak systolic strain;
LAX Z apical long-axis; midLat Z mid-lateral wall; midSept Z mid-septum.
Echocardiograph in CKD 801disease stages at which severe structural and functional
changes have already been established. In the general
population, however, GLS has been proven as a prognostic
predictor.68,69
We also demonstrated that GLS is a powerful prognostic
predictor in stable hemodialysis patients with preserved
LVEF and chronic peritoneal dialysis patients.38,70 Because
a less negative GLS (GLS  15%) was the independent
predictor of all-cause mortality and patients with a less
negative GLS had a higher cardiovascular mortality rate, we
highlighted the clinical application of GLS for risk assess-
ment in clinically stable hemodialysis patients with pre-
served LVEF. Furthermore, the combination of GLS and
interleukin-18 or cardiac troponin T may add incremental
prognostic information and facilitate risk stratification for
the outcomes and inform clinical decision making for stable
hemodialysis patients.9,71 However, we recognized that
there is lack of strong prognostic evidence of GLS in non-
dialysis CKD patients. To our knowledge, only one previous
study,72 which included only 121 patients with eGFR <60,
demonstrated that GLS was associated with all-cause mor-
tality in nondialysis CKD patients. Larger prospective cohort
studies are still warranted in this patient population.
A few studies indicated that myocardial strain and strain
rate may provide useful information regarding diastolic
function.73e76 However, we should note that while the
evaluation of diastolic function by deformation imaging
might be promising, more studies are needed to confirm its
incremental clinical value. Therefore, the ASE 2009
recommendation suggests that TDI-derived myocardial ve-
locity is still the preferred methodology to evaluate LV
diastolic function.31
Three-dimensional echocardiography (3DE) has been
validated to precisely and reproducibly interpret the com-
plex cardiac anatomy and function as well as to overcome
the limitations of conventional 2DE.77 For example, one of
the major advantages of 3DE is improvement in the accu-
racy of cardiac chamber volume and EF measurement by
diminishing geometric assumptions and errors resulting
from inadequate views.77,78 Although 3DE has been studiedfor years, nevertheless, it still lacks strong evidence of its
applications and clinical roles in CKD patients.79 A recent
3D-STE study demonstrated the ability of 3D-STE to detect
myocardial dysfunction in ESRD patients with preserved
LVEF; however, it did not prove that 3D-STE was superior to
2D-STE in detecting subclinical cardiac dysfunction. More-
over, it did not study the prognostic role of 3D-STE in CKD
patients.80
Although there is accumulating evidence that several
noninvasive markers are proved as prognostic indicators in
CKD patients,81e84 the head-to-head comparison studies
between echocardiography and other noninvasive markers
are limited in CKD patients. Nevertheless, we have to
acknowledge that biomarkers cannot replace echocardiog-
raphy but may play a complementary role in evaluating
cardiovascular risk of CKD patients.81
Limitations
There are some limitations of echocardiography, including
2DE and 3DE, to evaluate cardiac functions.74,75 Good
image quality is essential for accurate LV quantification.
Technical conditions, such as image quality, echocardio-
graphic resolution, artifacts, may significantly affect the
accuracy of cardiac measurement. In addition, although
many studies indicate the possible clinical roles of echo-
cardiography in CKD patients, there is no large cohort study
to show cost effectiveness of an echocardiographic study
and its impact on daily management. Therefore, it is pre-
mature to suggest routine echocardiographic study in CKD
patients now, especially in those without cardiac symptom/
sign. Further large-scale cohort study is necessary to vali-
date the clinical impact and applications of echocardio-
graphic study in CKD patients.
Conclusion
Table 1 summarizes the findings of previous studies
demonstrating that echocardiographic parameters are
prognostic predictors in CKD patients, which suggests that
Table 1 A summary of studies, which were cited in this review, on echocardiographic parameters as prognostic predictors in
CKD patients.
Study Studied
population
Echocardiographic parameter(s) Mean/median
follow-up
duration (y)
Sample
size
Outcome
Foley et al23 ESRD LV hypertrophy (LV mass index), LV dilatation (LV
end-diastolic volume index > 90 mL/m2), & LV
systolic dysfunction (FS  25%)
3.4 433 All-cause mortality
Wang et al24 Chronic PD LV mass index 3 222 HF hospitalization
due to
cardiovascular
congestion
Stack &
Saran35
New ESRD LV hypertrophy 2.0 2257 All-cause mortality
Foley et al36 ESRD LV end-diastolic volume & LV mass-to-volume ratio 3.4 433 Late mortality (>2 y
after starting
dialysis therapy)
London
et al37
HD  3 mo [ 10% LV mass 4.5 153 All-cause mortality,
CV mortality
Liu et al38 Chronic HD LV GLS 2.2 88 All-cause mortality,
CV mortality
Barberato &
Pecoits
Filho50
Chronic HD LAV index (32 mL/m2) 1.6 118 All-cause mortality
& nonfatal CV
eventsa
Chen et al51 CKD,
Stages 3e5
Left atrial diameter (LAD) > 4.7 cm, increased LVMI,
LVEF < 55%
1.1 505 CV eventsb
Farshid
et al52
CKD,
Stages 4 &
5
LV diastolic dysfunction (Grade 2) 2.9 153 All-cause mortality,
adverse CV eventsc
Liu et al70 Chronic PD LV GLS 2.5 106 MAEs, MACCEsd
Sung et al71 Chronic HD LV GLS 2.6 88 All-cause mortality
Krishnasamy
et al72
CKD &
non-CKD
LV GLS 5.2 447 (121
with
eGFR < 60)
All-cause mortality
Zoccali
et al84
ESRD on
regular
dialysis
LVEF & LV FS at the endocardial level & at midwall 3.4 254 Fatal & nonfatal CV
eventse
CKD Z chronic kidney disease; CV Z cardiovascular; ECG Z electrocardiogram; eGFR Z estimated glomerular filtration rate;
EF Z ejection fraction; ESRD Z end-stage renal disease; FS Z fractional shortening; GLS Z global peak systolic longitudinal strain;
HD Z hemodialysis; HF Z heart failure; LAD Z left atrial diameter; LAV Z left atrial volume; LV Z left ventricular; LVMI Z left
ventricular mass index; MAEs Z major adverse events; MACCEs Z major adverse cardiovascular cerebral events; PD Z peritoneal
dialysis.
a Nonfatal CV events include new coronary event (i.e., nonfatal acute myocardial infarction or angina pectoris with coronary stenosis
>50% on coronary angiography), ischemic or hemorrhagic stroke, and clinical diagnosis of congestive heart failure requiring
hospitalization.
b CV events include CV death, hospitalization for unstable angina, nonfatal myocardial infarction, sustained ventricular arrhythmia,
hospitalization for congestive heart failure, transient ischemia attack, and stroke.
c Adverse CV events include acute myocardial infarction, unstable angina, cardiac failure, cerebrovascular accident, percutaneous
coronary intervention, and cardiovascular death.
d MACCEs include cardiovascular death, cardiac hospitalization, and stroke. MAEs are defined as all-cause mortality and MACCEs.
e CV events include myocardial infarction, documented angina, heart failure, transient ischemic attacks or stroke, peripheral artery
disease, venous thrombosis, artery thrombosis, new onset of ECG-documented arrhythmia, and death.
802 Y.-W. Liu et al.echocardiography may play a pivotal role in assessing car-
diac morphology and functions in CKD patients. Although
STE with strain analysis and TDI can accurately access LV
systolic and diastolic function, respectively, there are
several pitfalls and limitations of each methodology. To
interpret echocardiographic parameters precisely in CKD
patients, it is important to consider patients’ age,underlying comorbidities, and any abnormalities noted in
the echocardiogram. In addition, further studies for
developing clinical risk stratification and therapeutic stra-
tegies, possibly using echocardiogram parameters to iden-
tify high-risk patients or to follow-up the therapeutic
effects, to improve CKD patients’ prognosis are still
warranted.
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